Oxytocin in Alcohol Use Disorder

This is an interventional other trial for Alcoholism focused on measuring Addiction, Oxytocin, Functional Magnetic Resonance Imaging (fMRI), Alcohol, Cue Reactivity Read More

• INCLUSION CRITERIA:
• 21-55 year old male subjects. Justification: women will not be included due to: 1) the confound of the estrogen-modulating effect of OT; 2) the need to control for menstrual cycle phase across repeated days of study procedures which would significantly limit the feasibility of the study
• Must meet DSM-5 criteria for AUD based on the SCID
• Right handed

EXCLUSION CRITERIA:

• Non-drinkers (alcohol-naive individuals or current abstainers).
• Currently seeking treatment to reduce or stop alcohol use.
• Current diagnosis of substance use disorder other than nicotine as determined by DSM-5.
• Current clinically significant major depression or anxiety; or lifetime diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or obsessive compulsive disorder.
• Lifetime history of suicide attempts.
• Contraindications for MRI scanning, including metal in body that are contraindicated for MRI (such as implants, pacemaker, prostheses, shrapnel, irremovable piercings), left-handedness, claustrophobia or unable to lie comfortably supine for up to 2 hours in the and MRI scanner as determined from history and physician examination and the MRI safety form.
• BMI>40 or if Investigators determine that subject s body shape precludes acquisition of an adequate MRI scan.
• Unable to provide a negative urine drug test (UDT).
• Medical contraindications: Current clinically significant disease, including CNS, seizures, cardiovascular, hypertension, arrhythmias, glaucoma, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders as determined by history and clinical exam at screening. Specifically, unstable hypertension, clinically significant EKG abnormalities, GFR rate > 60ml/min, liver cirrhosis, AST or ALT > 3X the upper normal limit, hemoglobin < 10.5 g/dl.
• Participants who have significant alcohol withdrawal symptoms as defined by CIWA-Ar>8.
• History of alcohol related seizures
• Requirement for or use in the past two weeks of psychoactive medications (four weeks for fluoxetine).
• Use of prescription or OTC medications known to interact with alcohol within 2 weeks of the study. These include, but may not be limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, anti-epileptics including phenytoin and phenobarbital codeine, and narcotics including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-cold preparations, which contain anti-histamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least 72 hours prior to each study session.
• History of hypersensitivity to oxytocin.
• Clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins
• Head trauma with loss of consciousness for more than 30 minutes.
• Any individuals with colorblindness that would prevent them from completing the Stroop task.
• Any other reason for which the Investigators will determine that it is not in the best interest of the participant to take part in this research.